 Joshua Thurman
Concepts (607)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Complement System Proteins | 41 | 2023 | 283 | 11.660 |
Why?
| | Complement Activation | 59 | 2023 | 340 | 11.120 |
Why?
| | Kidney Diseases | 23 | 2023 | 350 | 9.350 |
Why?
| | Complement Pathway, Alternative | 34 | 2022 | 114 | 6.680 |
Why?
| | Complement Factor H | 16 | 2022 | 60 | 5.270 |
Why?
| | Complement Inactivating Agents | 13 | 2023 | 41 | 4.910 |
Why?
| | Kidney | 31 | 2023 | 1188 | 4.630 |
Why?
| | Kidney Glomerulus | 15 | 2023 | 100 | 4.400 |
Why?
| | Reperfusion Injury | 15 | 2019 | 255 | 4.170 |
Why?
| | Complement Factor B | 25 | 2023 | 100 | 3.950 |
Why?
| | Glomerulonephritis | 9 | 2023 | 45 | 3.880 |
Why?
| | Complement C3 | 25 | 2023 | 188 | 3.040 |
Why?
| | Immunoglobulin M | 9 | 2023 | 246 | 3.030 |
Why?
| | Acute Kidney Injury | 12 | 2023 | 638 | 2.690 |
Why?
| | Glomerulosclerosis, Focal Segmental | 5 | 2022 | 29 | 2.640 |
Why?
| | Autoimmune Diseases | 8 | 2023 | 382 | 2.530 |
Why?
| | Atypical Hemolytic Uremic Syndrome | 6 | 2023 | 18 | 2.130 |
Why?
| | Receptors, Complement | 11 | 2022 | 111 | 1.760 |
Why?
| | Graft Rejection | 9 | 2019 | 513 | 1.740 |
Why?
| | Kidney Tubules | 7 | 2012 | 107 | 1.730 |
Why?
| | Lupus Nephritis | 7 | 2021 | 52 | 1.720 |
Why?
| | Receptor, Anaphylatoxin C5a | 6 | 2018 | 28 | 1.640 |
Why?
| | Nephrosis, Lipoid | 2 | 2022 | 10 | 1.590 |
Why?
| | Antibodies | 3 | 2019 | 371 | 1.580 |
Why?
| | Nephrotic Syndrome | 2 | 2022 | 24 | 1.570 |
Why?
| | Mice | 72 | 2023 | 14869 | 1.520 |
Why?
| | Animals | 102 | 2023 | 31706 | 1.500 |
Why?
| | Endothelial Cells | 5 | 2022 | 687 | 1.450 |
Why?
| | Complement C3b | 4 | 2023 | 30 | 1.410 |
Why?
| | Inflammation | 15 | 2021 | 2480 | 1.400 |
Why?
| | Epitopes | 8 | 2023 | 435 | 1.380 |
Why?
| | Immunosuppressive Agents | 6 | 2021 | 646 | 1.300 |
Why?
| | Mice, Knockout | 33 | 2022 | 2570 | 1.260 |
Why?
| | Epithelial Cells | 9 | 2022 | 951 | 1.220 |
Why?
| | Complement Inactivator Proteins | 4 | 2021 | 40 | 1.210 |
Why?
| | Complement C3d | 8 | 2023 | 60 | 1.200 |
Why?
| | Hemolytic-Uremic Syndrome | 4 | 2018 | 11 | 1.140 |
Why?
| | Antibodies, Monoclonal | 16 | 2023 | 1262 | 1.130 |
Why?
| | Mice, Inbred C57BL | 42 | 2022 | 4694 | 1.110 |
Why?
| | Contrast Media | 4 | 2018 | 345 | 1.100 |
Why?
| | Glomerulonephritis, Membranoproliferative | 3 | 2023 | 13 | 1.040 |
Why?
| | Complement Pathway, Classical | 3 | 2021 | 19 | 1.010 |
Why?
| | Humans | 95 | 2023 | 114689 | 1.010 |
Why?
| | Organ Transplantation | 2 | 2019 | 159 | 1.000 |
Why?
| | Thrombotic Microangiopathies | 4 | 2018 | 12 | 0.990 |
Why?
| | Cell-Derived Microparticles | 2 | 2018 | 57 | 0.990 |
Why?
| | Complement C5a | 6 | 2018 | 59 | 0.990 |
Why?
| | Fluorescent Antibody Technique | 5 | 2021 | 397 | 0.950 |
Why?
| | Endothelium, Vascular | 5 | 2020 | 847 | 0.870 |
Why?
| | Kidney Transplantation | 8 | 2019 | 541 | 0.840 |
Why?
| | Lupus Erythematosus, Systemic | 8 | 2022 | 219 | 0.840 |
Why?
| | Nephritis | 2 | 2013 | 20 | 0.840 |
Why?
| | Antigen-Antibody Complex | 3 | 2020 | 84 | 0.830 |
Why?
| | Magnetic Resonance Imaging | 5 | 2018 | 3053 | 0.810 |
Why?
| | Angiogenesis Inducing Agents | 2 | 2021 | 22 | 0.810 |
Why?
| | Disease Models, Animal | 29 | 2021 | 3535 | 0.790 |
Why?
| | Biomarkers | 15 | 2023 | 3408 | 0.760 |
Why?
| | Complement Membrane Attack Complex | 6 | 2018 | 33 | 0.750 |
Why?
| | Rhabdomyolysis | 1 | 2021 | 16 | 0.740 |
Why?
| | Cardiolipins | 1 | 2021 | 71 | 0.730 |
Why?
| | Molecular Targeted Therapy | 3 | 2018 | 347 | 0.730 |
Why?
| | Cyclosporine | 3 | 2019 | 161 | 0.670 |
Why?
| | Immunoglobulin G | 11 | 2023 | 770 | 0.660 |
Why?
| | Otitis Media | 5 | 2016 | 142 | 0.660 |
Why?
| | Hemoglobinuria, Paroxysmal | 2 | 2020 | 5 | 0.640 |
Why?
| | Kidney Failure, Chronic | 3 | 2021 | 489 | 0.640 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2021 | 663 | 0.630 |
Why?
| | Vascular System Injuries | 1 | 2019 | 66 | 0.630 |
Why?
| | Retinal Pigment Epithelium | 4 | 2017 | 58 | 0.630 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2020 | 211 | 0.620 |
Why?
| | Complement Factor D | 1 | 2018 | 26 | 0.610 |
Why?
| | Pneumococcal Infections | 4 | 2014 | 91 | 0.600 |
Why?
| | Autoantibodies | 10 | 2023 | 1346 | 0.600 |
Why?
| | Doxorubicin | 4 | 2023 | 285 | 0.590 |
Why?
| | Glomerulonephritis, IGA | 1 | 2017 | 7 | 0.590 |
Why?
| | B-Lymphocytes | 7 | 2022 | 766 | 0.570 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 385 | 0.570 |
Why?
| | Transplantation, Homologous | 3 | 2019 | 377 | 0.560 |
Why?
| | Rheumatic Diseases | 1 | 2017 | 49 | 0.560 |
Why?
| | Liver Neoplasms | 1 | 2020 | 506 | 0.530 |
Why?
| | Annexin A2 | 1 | 2016 | 10 | 0.520 |
Why?
| | Renal Insufficiency | 1 | 2018 | 137 | 0.520 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 82 | 0.520 |
Why?
| | Streptococcus pneumoniae | 4 | 2014 | 133 | 0.510 |
Why?
| | Peptide Fragments | 1 | 2019 | 666 | 0.500 |
Why?
| | Pregnancy Complications | 3 | 2018 | 429 | 0.490 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 1141 | 0.490 |
Why?
| | Mice, Inbred BALB C | 10 | 2023 | 1144 | 0.480 |
Why?
| | Cardiac Surgical Procedures | 1 | 2019 | 414 | 0.480 |
Why?
| | Male | 46 | 2022 | 55599 | 0.470 |
Why?
| | Magnetite Nanoparticles | 2 | 2011 | 28 | 0.470 |
Why?
| | Female | 42 | 2023 | 59511 | 0.430 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2018 | 486 | 0.420 |
Why?
| | Liver | 2 | 2020 | 1637 | 0.420 |
Why?
| | Immune Complex Diseases | 1 | 2012 | 7 | 0.420 |
Why?
| | Complement C3a | 3 | 2014 | 33 | 0.410 |
Why?
| | Autoimmunity | 5 | 2022 | 813 | 0.410 |
Why?
| | Nanoparticles | 2 | 2013 | 313 | 0.410 |
Why?
| | Receptors, Complement 3b | 6 | 2016 | 81 | 0.400 |
Why?
| | Peptides, Cyclic | 1 | 2014 | 253 | 0.400 |
Why?
| | Immunity, Humoral | 1 | 2013 | 112 | 0.400 |
Why?
| | Molecular Imaging | 1 | 2012 | 50 | 0.390 |
Why?
| | Complement C1q | 3 | 2014 | 36 | 0.390 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2019 | 797 | 0.380 |
Why?
| | Toll-Like Receptor 2 | 1 | 2012 | 110 | 0.380 |
Why?
| | Complement C2 | 2 | 2011 | 6 | 0.370 |
Why?
| | Oxidative Stress | 7 | 2019 | 1076 | 0.350 |
Why?
| | CD55 Antigens | 3 | 2020 | 27 | 0.350 |
Why?
| | Blotting, Western | 7 | 2016 | 1147 | 0.340 |
Why?
| | Ferrosoferric Oxide | 1 | 2010 | 25 | 0.340 |
Why?
| | B-Lymphocyte Subsets | 1 | 2010 | 68 | 0.340 |
Why?
| | Cell Membrane | 4 | 2022 | 680 | 0.340 |
Why?
| | Toll-Like Receptor 4 | 1 | 2012 | 287 | 0.340 |
Why?
| | Plasmodium falciparum | 3 | 1998 | 27 | 0.340 |
Why?
| | Disease Susceptibility | 2 | 2020 | 316 | 0.330 |
Why?
| | Protozoan Proteins | 3 | 1998 | 62 | 0.330 |
Why?
| | Cytokines | 5 | 2019 | 1841 | 0.320 |
Why?
| | Signal Transduction | 9 | 2020 | 4513 | 0.320 |
Why?
| | Properdin | 2 | 2020 | 8 | 0.310 |
Why?
| | Diarrhea | 1 | 2009 | 171 | 0.310 |
Why?
| | Antibody Specificity | 2 | 2021 | 176 | 0.310 |
Why?
| | Adult | 13 | 2023 | 30550 | 0.310 |
Why?
| | Epidermolysis Bullosa Acquisita | 3 | 2018 | 6 | 0.300 |
Why?
| | Complement C4 | 5 | 2021 | 25 | 0.300 |
Why?
| | Receptors, Complement 3d | 4 | 2022 | 130 | 0.300 |
Why?
| | Uremia | 2 | 2021 | 14 | 0.290 |
Why?
| | Graft Survival | 4 | 2019 | 446 | 0.290 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2008 | 60 | 0.290 |
Why?
| | Metabolomics | 4 | 2019 | 521 | 0.290 |
Why?
| | Complement C3b Inactivator Proteins | 2 | 2017 | 9 | 0.290 |
Why?
| | Phagocytosis | 4 | 2023 | 350 | 0.290 |
Why?
| | Podocytes | 2 | 2020 | 44 | 0.280 |
Why?
| | Chemokines, CXC | 1 | 2007 | 60 | 0.280 |
Why?
| | Kidney Tubules, Proximal | 2 | 2016 | 113 | 0.270 |
Why?
| | Adaptive Immunity | 2 | 2019 | 155 | 0.270 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2007 | 109 | 0.270 |
Why?
| | Pilot Projects | 3 | 2021 | 1373 | 0.270 |
Why?
| | Flow Cytometry | 4 | 2022 | 1083 | 0.270 |
Why?
| | Cells, Cultured | 6 | 2019 | 3886 | 0.270 |
Why?
| | Protein Binding | 6 | 2019 | 1890 | 0.270 |
Why?
| | Cardiopulmonary Bypass | 1 | 2008 | 178 | 0.270 |
Why?
| | Immune System Diseases | 1 | 2006 | 32 | 0.260 |
Why?
| | Immunohistochemistry | 5 | 2016 | 1629 | 0.260 |
Why?
| | Chemokines | 1 | 2007 | 216 | 0.250 |
Why?
| | NF-kappa B | 3 | 2016 | 641 | 0.250 |
Why?
| | Tandem Mass Spectrometry | 3 | 2019 | 412 | 0.250 |
Why?
| | Organ Specificity | 3 | 2020 | 268 | 0.250 |
Why?
| | Cell Line | 6 | 2017 | 2637 | 0.250 |
Why?
| | Biopsy | 3 | 2019 | 1036 | 0.240 |
Why?
| | Child | 11 | 2023 | 18415 | 0.240 |
Why?
| | Kidney Tubular Necrosis, Acute | 1 | 2005 | 22 | 0.240 |
Why?
| | Antibodies, Antiphospholipid | 1 | 2005 | 21 | 0.240 |
Why?
| | Fetal Death | 1 | 2005 | 50 | 0.240 |
Why?
| | Caspases | 1 | 2006 | 245 | 0.240 |
Why?
| | Disease Progression | 4 | 2017 | 2380 | 0.240 |
Why?
| | Immunity, Innate | 6 | 2017 | 720 | 0.230 |
Why?
| | Chromatography, Liquid | 2 | 2016 | 347 | 0.230 |
Why?
| | Macular Degeneration | 3 | 2012 | 152 | 0.230 |
Why?
| | Complement C3-C5 Convertases | 3 | 2016 | 19 | 0.230 |
Why?
| | Middle Aged | 10 | 2022 | 26737 | 0.230 |
Why?
| | Rats | 8 | 2021 | 4958 | 0.230 |
Why?
| | Antibodies, Protozoan | 3 | 1998 | 30 | 0.220 |
Why?
| | Prognosis | 5 | 2022 | 3329 | 0.220 |
Why?
| | Receptors, Angiotensin | 1 | 2003 | 9 | 0.220 |
Why?
| | Mice, Inbred MRL lpr | 4 | 2022 | 37 | 0.210 |
Why?
| | Case-Control Studies | 2 | 2021 | 3003 | 0.210 |
Why?
| | Tacrolimus | 2 | 2014 | 134 | 0.210 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2003 | 76 | 0.210 |
Why?
| | Ischemia | 3 | 2015 | 362 | 0.210 |
Why?
| | Proteomics | 4 | 2018 | 836 | 0.200 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2003 | 179 | 0.200 |
Why?
| | Allografts | 2 | 2019 | 122 | 0.200 |
Why?
| | Lymphoid Tissue | 1 | 2022 | 62 | 0.190 |
Why?
| | CD59 Antigens | 3 | 2011 | 21 | 0.190 |
Why?
| | Antigens, Protozoan | 2 | 1998 | 19 | 0.190 |
Why?
| | Apoptosis | 2 | 2011 | 2363 | 0.190 |
Why?
| | Glutamic Acid | 1 | 2023 | 211 | 0.190 |
Why?
| | Protein Processing, Post-Translational | 3 | 2023 | 399 | 0.190 |
Why?
| | Organic Anion Transporters | 1 | 2021 | 15 | 0.190 |
Why?
| | Myoglobin | 1 | 2021 | 14 | 0.190 |
Why?
| | Aged | 7 | 2021 | 19074 | 0.190 |
Why?
| | Immune System | 1 | 2022 | 172 | 0.190 |
Why?
| | Malaria, Falciparum | 2 | 1998 | 25 | 0.190 |
Why?
| | Extracellular Vesicles | 1 | 2022 | 83 | 0.180 |
Why?
| | Choroidal Neovascularization | 2 | 2013 | 44 | 0.180 |
Why?
| | Proteinuria | 3 | 2012 | 77 | 0.180 |
Why?
| | Paraffin Embedding | 1 | 2021 | 21 | 0.180 |
Why?
| | Formaldehyde | 1 | 2021 | 46 | 0.180 |
Why?
| | Frozen Sections | 1 | 2021 | 24 | 0.180 |
Why?
| | Albuminuria | 2 | 2015 | 164 | 0.180 |
Why?
| | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2020 | 20 | 0.180 |
Why?
| | Treatment Outcome | 3 | 2021 | 9088 | 0.180 |
Why?
| | Anemia, Hemolytic | 1 | 2020 | 18 | 0.180 |
Why?
| | Dendritic Cells | 2 | 2022 | 435 | 0.180 |
Why?
| | Staining and Labeling | 1 | 2021 | 134 | 0.180 |
Why?
| | Up-Regulation | 3 | 2019 | 808 | 0.170 |
Why?
| | Critical Illness | 2 | 2023 | 646 | 0.170 |
Why?
| | T-Lymphocytes | 5 | 2022 | 1737 | 0.170 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 1 | 2019 | 10 | 0.160 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2012 | 498 | 0.160 |
Why?
| | Transplantation, Heterologous | 1 | 2019 | 181 | 0.160 |
Why?
| | Urinalysis | 1 | 2019 | 64 | 0.160 |
Why?
| | Sepsis | 2 | 2016 | 509 | 0.160 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 165 | 0.160 |
Why?
| | Iodine Radioisotopes | 1 | 2019 | 125 | 0.160 |
Why?
| | Severity of Illness Index | 3 | 2018 | 2540 | 0.160 |
Why?
| | Complement C4a | 1 | 2018 | 6 | 0.160 |
Why?
| | North America | 1 | 2019 | 256 | 0.150 |
Why?
| | Lung | 5 | 2019 | 3561 | 0.150 |
Why?
| | Complement C5 | 3 | 2020 | 73 | 0.150 |
Why?
| | Vascular Remodeling | 1 | 2020 | 153 | 0.150 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 923 | 0.150 |
Why?
| | Erythrocytes | 2 | 2020 | 591 | 0.150 |
Why?
| | Adolescent | 7 | 2021 | 17848 | 0.150 |
Why?
| | Purpura, Thrombotic Thrombocytopenic | 1 | 2018 | 8 | 0.150 |
Why?
| | Granulocytes | 2 | 2016 | 77 | 0.150 |
Why?
| | HLA Antigens | 1 | 2019 | 225 | 0.150 |
Why?
| | Organelles | 1 | 1998 | 51 | 0.150 |
Why?
| | Glomerular Filtration Rate | 2 | 2018 | 604 | 0.140 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 36 | 0.140 |
Why?
| | Cyclophilins | 1 | 2017 | 29 | 0.140 |
Why?
| | Complement Pathway, Mannose-Binding Lectin | 1 | 2017 | 24 | 0.140 |
Why?
| | Gene Expression | 6 | 2017 | 1421 | 0.140 |
Why?
| | Brain Injuries | 3 | 2007 | 461 | 0.140 |
Why?
| | Cell Differentiation | 2 | 2022 | 1701 | 0.140 |
Why?
| | Brachial Artery | 1 | 2018 | 176 | 0.140 |
Why?
| | Diethylhexyl Phthalate | 1 | 2017 | 9 | 0.140 |
Why?
| | Lipopolysaccharides | 3 | 2015 | 823 | 0.140 |
Why?
| | Macrophages | 3 | 2013 | 1263 | 0.140 |
Why?
| | Blood Pressure | 1 | 2003 | 1538 | 0.140 |
Why?
| | Prospective Studies | 4 | 2023 | 6220 | 0.140 |
Why?
| | Interferon-beta | 2 | 2007 | 79 | 0.140 |
Why?
| | Choroiditis | 1 | 2016 | 6 | 0.140 |
Why?
| | Bleomycin | 1 | 2018 | 228 | 0.130 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 932 | 0.130 |
Why?
| | Benzhydryl Compounds | 1 | 2017 | 60 | 0.130 |
Why?
| | Arthritis, Experimental | 2 | 2009 | 130 | 0.130 |
Why?
| | Cell Aggregation | 1 | 2016 | 24 | 0.130 |
Why?
| | Tuberculosis | 1 | 2019 | 241 | 0.130 |
Why?
| | Phenols | 1 | 2017 | 82 | 0.130 |
Why?
| | Mycobacterium tuberculosis | 1 | 2019 | 268 | 0.130 |
Why?
| | MicroRNAs | 1 | 2022 | 600 | 0.130 |
Why?
| | Collagen Type VII | 3 | 2018 | 13 | 0.130 |
Why?
| | Mucin-5B | 1 | 2018 | 183 | 0.130 |
Why?
| | Ear, Middle | 3 | 2012 | 89 | 0.130 |
Why?
| | Complement C5b | 1 | 2015 | 4 | 0.130 |
Why?
| | Interferon-alpha | 2 | 2007 | 186 | 0.130 |
Why?
| | Carboxypeptidases | 1 | 2015 | 12 | 0.130 |
Why?
| | Inflammation Mediators | 3 | 2019 | 477 | 0.130 |
Why?
| | Immunoprecipitation | 1 | 2016 | 151 | 0.130 |
Why?
| | Oncolytic Viruses | 1 | 2015 | 5 | 0.120 |
Why?
| | Oncolytic Virotherapy | 1 | 2015 | 8 | 0.120 |
Why?
| | Hypersensitivity, Delayed | 1 | 2015 | 27 | 0.120 |
Why?
| | Vasodilation | 1 | 2018 | 419 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 398 | 0.120 |
Why?
| | Ultrasonography | 1 | 2018 | 634 | 0.120 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 97 | 0.120 |
Why?
| | Fibroblasts | 1 | 2020 | 838 | 0.120 |
Why?
| | Vaccinia virus | 1 | 2015 | 27 | 0.120 |
Why?
| | Analysis of Variance | 2 | 2010 | 1226 | 0.120 |
Why?
| | Hypertension | 1 | 2003 | 1056 | 0.120 |
Why?
| | Urinary Tract Infections | 1 | 2016 | 134 | 0.120 |
Why?
| | Complement Fixation Tests | 1 | 2014 | 6 | 0.120 |
Why?
| | Recombinant Proteins | 3 | 2015 | 1230 | 0.120 |
Why?
| | Abortion, Spontaneous | 2 | 2006 | 90 | 0.120 |
Why?
| | Eustachian Tube | 1 | 2014 | 4 | 0.120 |
Why?
| | Shiga Toxin 2 | 1 | 2014 | 1 | 0.120 |
Why?
| | Edema | 1 | 2015 | 119 | 0.120 |
Why?
| | Mast Cells | 1 | 2015 | 116 | 0.120 |
Why?
| | Neutrophils | 2 | 2013 | 1176 | 0.110 |
Why?
| | Immunoglobulins | 2 | 2020 | 143 | 0.110 |
Why?
| | Mesangial Cells | 1 | 2013 | 2 | 0.110 |
Why?
| | Models, Immunological | 2 | 2012 | 92 | 0.110 |
Why?
| | Orthomyxoviridae Infections | 1 | 2014 | 54 | 0.110 |
Why?
| | Diagnostic Imaging | 1 | 2016 | 275 | 0.110 |
Why?
| | Aquaporins | 2 | 2003 | 8 | 0.110 |
Why?
| | Mycophenolic Acid | 1 | 2014 | 77 | 0.110 |
Why?
| | Recurrence | 1 | 2016 | 935 | 0.110 |
Why?
| | Cricetulus | 2 | 2010 | 97 | 0.110 |
Why?
| | CHO Cells | 2 | 2010 | 138 | 0.110 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 383 | 0.110 |
Why?
| | Pregnancy | 4 | 2018 | 5518 | 0.110 |
Why?
| | Blood Platelets | 1 | 2016 | 351 | 0.110 |
Why?
| | Genetic Variation | 1 | 2018 | 870 | 0.110 |
Why?
| | Cricetinae | 2 | 2010 | 253 | 0.110 |
Why?
| | Genotype | 1 | 2018 | 1760 | 0.110 |
Why?
| | Acute Disease | 3 | 2014 | 911 | 0.110 |
Why?
| | Serum | 1 | 2013 | 57 | 0.100 |
Why?
| | Surface Plasmon Resonance | 1 | 2013 | 81 | 0.100 |
Why?
| | Lymphocyte Activation | 5 | 2022 | 1037 | 0.100 |
Why?
| | Amino Acids | 1 | 2016 | 448 | 0.100 |
Why?
| | Sirolimus | 1 | 2014 | 181 | 0.100 |
Why?
| | Skin | 2 | 2015 | 655 | 0.100 |
Why?
| | Lymphocyte Depletion | 1 | 2013 | 116 | 0.100 |
Why?
| | Mass Spectrometry | 1 | 2016 | 633 | 0.100 |
Why?
| | Embryo, Nonmammalian | 1 | 2013 | 173 | 0.100 |
Why?
| | Sodium Chloride, Dietary | 1 | 2012 | 30 | 0.100 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 1 | 2013 | 51 | 0.100 |
Why?
| | Macrophages, Alveolar | 1 | 2015 | 348 | 0.100 |
Why?
| | Drug Monitoring | 1 | 2013 | 184 | 0.100 |
Why?
| | Ultraviolet Rays | 1 | 2015 | 363 | 0.100 |
Why?
| | Rhadinovirus | 1 | 2012 | 16 | 0.100 |
Why?
| | Rituximab | 1 | 2013 | 150 | 0.100 |
Why?
| | Recombinant Fusion Proteins | 2 | 2009 | 616 | 0.100 |
Why?
| | Mitochondria | 1 | 2017 | 747 | 0.100 |
Why?
| | Acute Lung Injury | 1 | 2015 | 299 | 0.100 |
Why?
| | Myocytes, Cardiac | 2 | 2013 | 449 | 0.100 |
Why?
| | Tumor Virus Infections | 1 | 2012 | 43 | 0.100 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2018 | 505 | 0.100 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2017 | 959 | 0.100 |
Why?
| | Feasibility Studies | 2 | 2015 | 740 | 0.090 |
Why?
| | Bronchial Hyperreactivity | 1 | 2011 | 95 | 0.090 |
Why?
| | Adenocarcinoma | 1 | 2017 | 795 | 0.090 |
Why?
| | Spleen | 1 | 2013 | 487 | 0.090 |
Why?
| | Extracellular Fluid | 1 | 2011 | 30 | 0.090 |
Why?
| | Tissue Distribution | 3 | 2019 | 286 | 0.090 |
Why?
| | Down-Regulation | 4 | 2020 | 594 | 0.090 |
Why?
| | Herpesviridae Infections | 1 | 2012 | 138 | 0.090 |
Why?
| | Plasma Exchange | 1 | 2010 | 12 | 0.090 |
Why?
| | In Situ Nick-End Labeling | 1 | 2010 | 119 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1342 | 0.090 |
Why?
| | Blister | 2 | 2008 | 43 | 0.090 |
Why?
| | Membrane Cofactor Protein | 1 | 2010 | 12 | 0.090 |
Why?
| | Blood Bactericidal Activity | 1 | 2010 | 36 | 0.090 |
Why?
| | Opsonin Proteins | 1 | 2010 | 25 | 0.090 |
Why?
| | Colony Count, Microbial | 1 | 2010 | 111 | 0.080 |
Why?
| | Dextrans | 1 | 2010 | 73 | 0.080 |
Why?
| | Host-Pathogen Interactions | 1 | 2012 | 295 | 0.080 |
Why?
| | Time Factors | 4 | 2015 | 6116 | 0.080 |
Why?
| | Collagen Type II | 1 | 2009 | 48 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2286 | 0.080 |
Why?
| | Microbial Viability | 1 | 2010 | 79 | 0.080 |
Why?
| | Osteoarthritis | 1 | 2011 | 171 | 0.080 |
Why?
| | RNA, Messenger | 6 | 2022 | 2553 | 0.080 |
Why?
| | Antibody Formation | 1 | 2010 | 266 | 0.080 |
Why?
| | Image Enhancement | 1 | 2010 | 159 | 0.080 |
Why?
| | Hypertension, Pulmonary | 1 | 2020 | 1729 | 0.080 |
Why?
| | Cell Hypoxia | 1 | 2010 | 221 | 0.080 |
Why?
| | Insulin Resistance | 1 | 2017 | 1072 | 0.080 |
Why?
| | Microscopy, Fluorescence | 1 | 2010 | 396 | 0.080 |
Why?
| | Young Adult | 2 | 2021 | 10470 | 0.080 |
Why?
| | Neurons | 2 | 2006 | 1280 | 0.080 |
Why?
| | Liver Regeneration | 1 | 2008 | 29 | 0.080 |
Why?
| | Bacillus cereus | 1 | 2008 | 5 | 0.080 |
Why?
| | Allergens | 1 | 2011 | 413 | 0.080 |
Why?
| | Blood-Retinal Barrier | 1 | 2008 | 13 | 0.080 |
Why?
| | Hemolysis | 2 | 2020 | 146 | 0.070 |
Why?
| | Bacteremia | 1 | 2010 | 160 | 0.070 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2007 | 23 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 4 | 2010 | 2086 | 0.070 |
Why?
| | Gene Expression Profiling | 3 | 2011 | 1518 | 0.070 |
Why?
| | Bronchiolitis Obliterans | 1 | 2007 | 66 | 0.070 |
Why?
| | Binding Sites | 3 | 2016 | 1168 | 0.070 |
Why?
| | Chemokine CXCL2 | 1 | 2007 | 41 | 0.070 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2009 | 156 | 0.070 |
Why?
| | Chemokine CXCL1 | 1 | 2007 | 68 | 0.070 |
Why?
| | Kidney Function Tests | 1 | 2007 | 140 | 0.070 |
Why?
| | Cloning, Molecular | 2 | 2017 | 522 | 0.070 |
Why?
| | Kidney Concentrating Ability | 2 | 2003 | 3 | 0.070 |
Why?
| | Poly I-C | 1 | 2006 | 51 | 0.070 |
Why?
| | Leukocytes | 1 | 2008 | 276 | 0.070 |
Why?
| | Immunization, Passive | 1 | 2006 | 73 | 0.070 |
Why?
| | Renal Circulation | 1 | 2006 | 53 | 0.060 |
Why?
| | Renal Dialysis | 1 | 2009 | 374 | 0.060 |
Why?
| | Respiratory Hypersensitivity | 1 | 2006 | 60 | 0.060 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2010 | 685 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 3 | 2006 | 2218 | 0.060 |
Why?
| | Mice, Transgenic | 3 | 2017 | 1949 | 0.060 |
Why?
| | Mutation | 1 | 2016 | 3346 | 0.060 |
Why?
| | Antigens, Surface | 1 | 2006 | 146 | 0.060 |
Why?
| | Nephrectomy | 1 | 2006 | 150 | 0.060 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2019 | 470 | 0.060 |
Why?
| | Lung Transplantation | 1 | 2007 | 246 | 0.060 |
Why?
| | Complement C6 | 2 | 2018 | 9 | 0.060 |
Why?
| | Nitric Oxide | 1 | 2010 | 823 | 0.060 |
Why?
| | Membrane Transport Proteins | 2 | 2003 | 138 | 0.060 |
Why?
| | Placental Insufficiency | 1 | 2006 | 102 | 0.060 |
Why?
| | Neuroprotective Agents | 1 | 2006 | 104 | 0.060 |
Why?
| | Basement Membrane | 1 | 2005 | 30 | 0.060 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2177 | 0.060 |
Why?
| | Random Allocation | 1 | 2006 | 335 | 0.060 |
Why?
| | Probability | 1 | 2006 | 289 | 0.060 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2005 | 16 | 0.060 |
Why?
| | Epitope Mapping | 1 | 2005 | 51 | 0.060 |
Why?
| | Brain | 2 | 2006 | 2371 | 0.060 |
Why?
| | Pulmonary Fibrosis | 1 | 2007 | 323 | 0.060 |
Why?
| | Age Factors | 1 | 2011 | 2894 | 0.060 |
Why?
| | Membrane Proteins | 1 | 2010 | 1019 | 0.060 |
Why?
| | Lung Injury | 1 | 2006 | 198 | 0.060 |
Why?
| | Collagen | 1 | 2006 | 415 | 0.060 |
Why?
| | Toll-Like Receptors | 2 | 2016 | 167 | 0.060 |
Why?
| | Receptors, Cell Surface | 1 | 2006 | 355 | 0.060 |
Why?
| | Myocardium | 1 | 2009 | 913 | 0.060 |
Why?
| | Compulsive Behavior | 1 | 2003 | 5 | 0.060 |
Why?
| | Drinking Behavior | 1 | 2003 | 10 | 0.060 |
Why?
| | Antiphospholipid Syndrome | 1 | 2003 | 26 | 0.050 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2003 | 20 | 0.050 |
Why?
| | Annexins | 1 | 2023 | 3 | 0.050 |
Why?
| | Racemethionine | 1 | 2023 | 3 | 0.050 |
Why?
| | Energy Metabolism | 2 | 2019 | 731 | 0.050 |
Why?
| | Sodium-Potassium-Chloride Symporters | 1 | 2003 | 9 | 0.050 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 44 | 0.050 |
Why?
| | Complement C9 | 1 | 2003 | 5 | 0.050 |
Why?
| | Blood Urea Nitrogen | 1 | 2003 | 51 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2010 | 1880 | 0.050 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2016 | 345 | 0.050 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2023 | 195 | 0.050 |
Why?
| | Cartilage, Articular | 1 | 2006 | 289 | 0.050 |
Why?
| | Hypothyroidism | 1 | 2003 | 64 | 0.050 |
Why?
| | Sodium | 1 | 2003 | 183 | 0.050 |
Why?
| | Carrier Proteins | 2 | 2003 | 695 | 0.050 |
Why?
| | Methionine | 1 | 2023 | 144 | 0.050 |
Why?
| | Neutralization Tests | 2 | 2015 | 63 | 0.050 |
Why?
| | Immunoglobulin Isotypes | 1 | 2022 | 32 | 0.050 |
Why?
| | HLA-D Antigens | 1 | 2022 | 34 | 0.050 |
Why?
| | Ubiquitination | 1 | 2022 | 86 | 0.050 |
Why?
| | Mice, Inbred C3H | 1 | 2022 | 239 | 0.050 |
Why?
| | Imatinib Mesylate | 1 | 2021 | 63 | 0.050 |
Why?
| | Fetal Growth Retardation | 1 | 2006 | 467 | 0.050 |
Why?
| | Antigen Presentation | 1 | 2022 | 188 | 0.050 |
Why?
| | Cholecalciferol | 1 | 2021 | 47 | 0.050 |
Why?
| | Phospholipase D | 1 | 2020 | 7 | 0.050 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2022 | 139 | 0.050 |
Why?
| | Amino Acid Sequence | 2 | 2010 | 1982 | 0.040 |
Why?
| | Child, Preschool | 2 | 2015 | 9116 | 0.040 |
Why?
| | Antibodies, Blocking | 1 | 2020 | 32 | 0.040 |
Why?
| | Cell Line, Transformed | 1 | 2020 | 133 | 0.040 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2022 | 352 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2003 | 951 | 0.040 |
Why?
| | Reactive Oxygen Species | 2 | 2013 | 531 | 0.040 |
Why?
| | Particle Size | 1 | 2021 | 317 | 0.040 |
Why?
| | Cell Movement | 2 | 2015 | 869 | 0.040 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2020 | 89 | 0.040 |
Why?
| | Actin Cytoskeleton | 1 | 2020 | 93 | 0.040 |
Why?
| | Cell Line, Tumor | 2 | 2017 | 2710 | 0.040 |
Why?
| | Dinoprost | 1 | 2019 | 31 | 0.040 |
Why?
| | Mice, Congenic | 2 | 2010 | 21 | 0.040 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 140 | 0.040 |
Why?
| | Mice, 129 Strain | 1 | 2019 | 75 | 0.040 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2020 | 160 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2015 | 590 | 0.040 |
Why?
| | Immunoblotting | 2 | 2010 | 283 | 0.040 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2019 | 170 | 0.040 |
Why?
| | Brefeldin A | 1 | 1998 | 14 | 0.040 |
Why?
| | Cyclopentanes | 1 | 1998 | 15 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 299 | 0.040 |
Why?
| | Interleukin-1beta | 1 | 2020 | 370 | 0.040 |
Why?
| | Cell Compartmentation | 1 | 1998 | 51 | 0.040 |
Why?
| | Immunity, Active | 1 | 1998 | 9 | 0.040 |
Why?
| | A549 Cells | 1 | 2018 | 51 | 0.040 |
Why?
| | Aotidae | 1 | 1998 | 7 | 0.040 |
Why?
| | Protein Synthesis Inhibitors | 1 | 1998 | 42 | 0.040 |
Why?
| | Parasitemia | 1 | 1998 | 9 | 0.040 |
Why?
| | Immunodominant Epitopes | 1 | 1998 | 25 | 0.040 |
Why?
| | Vitamin D | 1 | 2021 | 341 | 0.040 |
Why?
| | Self Tolerance | 1 | 2017 | 28 | 0.040 |
Why?
| | Mice, Inbred Strains | 2 | 2010 | 396 | 0.040 |
Why?
| | Macrolides | 1 | 1998 | 56 | 0.040 |
Why?
| | Ligands | 1 | 2019 | 562 | 0.040 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2018 | 61 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2021 | 617 | 0.040 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1998 | 353 | 0.030 |
Why?
| | Immunomodulation | 1 | 2017 | 84 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2017 | 146 | 0.030 |
Why?
| | DNA Damage | 1 | 2019 | 351 | 0.030 |
Why?
| | Germinal Center | 1 | 2017 | 48 | 0.030 |
Why?
| | Recombination, Genetic | 1 | 1998 | 176 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 164 | 0.030 |
Why?
| | Infant | 1 | 2009 | 7963 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2015 | 1140 | 0.030 |
Why?
| | T-Box Domain Proteins | 1 | 2017 | 92 | 0.030 |
Why?
| | Epithelial Sodium Channels | 1 | 2016 | 12 | 0.030 |
Why?
| | Biological Transport, Active | 1 | 2016 | 71 | 0.030 |
Why?
| | Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 1 | 2015 | 4 | 0.030 |
Why?
| | Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2015 | 8 | 0.030 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 179 | 0.030 |
Why?
| | Capillary Leak Syndrome | 1 | 2015 | 13 | 0.030 |
Why?
| | Sulfones | 1 | 2016 | 97 | 0.030 |
Why?
| | Potassium Channels | 1 | 2016 | 121 | 0.030 |
Why?
| | Nitriles | 1 | 2016 | 149 | 0.030 |
Why?
| | Protein Kinases | 1 | 2017 | 307 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2017 | 698 | 0.030 |
Why?
| | Injections, Intralesional | 1 | 2015 | 32 | 0.030 |
Why?
| | Fetus | 2 | 2012 | 700 | 0.030 |
Why?
| | Smallpox Vaccine | 1 | 2015 | 22 | 0.030 |
Why?
| | Macaca fascicularis | 1 | 2015 | 50 | 0.030 |
Why?
| | Vero Cells | 1 | 2015 | 63 | 0.030 |
Why?
| | Sunburn | 1 | 2015 | 25 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2015 | 201 | 0.030 |
Why?
| | DNA Methylation | 1 | 2019 | 495 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2006 | 213 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2015 | 206 | 0.030 |
Why?
| | Rats, Inbred F344 | 1 | 2015 | 241 | 0.030 |
Why?
| | Rats, Inbred WF | 1 | 2014 | 5 | 0.030 |
Why?
| | Sex Factors | 1 | 2019 | 1715 | 0.030 |
Why?
| | Pyridones | 1 | 2015 | 123 | 0.030 |
Why?
| | Cecum | 1 | 2013 | 32 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1131 | 0.030 |
Why?
| | Hypoxia | 1 | 2020 | 958 | 0.030 |
Why?
| | Water Deprivation | 2 | 2003 | 8 | 0.030 |
Why?
| | HeLa Cells | 1 | 2015 | 562 | 0.030 |
Why?
| | Drug Synergism | 1 | 2014 | 316 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2013 | 271 | 0.030 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2013 | 90 | 0.030 |
Why?
| | Molecular Sequence Data | 1 | 1998 | 2785 | 0.030 |
Why?
| | International Cooperation | 1 | 2013 | 171 | 0.030 |
Why?
| | Coinfection | 1 | 2014 | 120 | 0.030 |
Why?
| | Complement C4b-Binding Protein | 1 | 2012 | 3 | 0.030 |
Why?
| | Ion Transport | 1 | 2012 | 55 | 0.030 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2012 | 100 | 0.030 |
Why?
| | Otitis | 1 | 2012 | 9 | 0.030 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2014 | 139 | 0.030 |
Why?
| | Glucose | 1 | 2017 | 897 | 0.030 |
Why?
| | Gene Deletion | 1 | 2014 | 356 | 0.030 |
Why?
| | Gluconeogenesis | 1 | 2012 | 62 | 0.030 |
Why?
| | Demyelinating Diseases | 1 | 2013 | 75 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 296 | 0.020 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2011 | 23 | 0.020 |
Why?
| | Synovial Fluid | 1 | 2011 | 56 | 0.020 |
Why?
| | Phosphates | 1 | 2012 | 159 | 0.020 |
Why?
| | Antibodies, Viral | 1 | 2015 | 520 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2014 | 343 | 0.020 |
Why?
| | Rats, Wistar | 1 | 2012 | 368 | 0.020 |
Why?
| | Ovalbumin | 1 | 2011 | 161 | 0.020 |
Why?
| | Glycolysis | 1 | 2012 | 227 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2012 | 149 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2013 | 381 | 0.020 |
Why?
| | Joints | 1 | 2011 | 84 | 0.020 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 157 | 0.020 |
Why?
| | Needs Assessment | 1 | 2012 | 314 | 0.020 |
Why?
| | Monitoring, Physiologic | 1 | 2012 | 249 | 0.020 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2012 | 473 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2010 | 95 | 0.020 |
Why?
| | Glycosylation | 1 | 2010 | 130 | 0.020 |
Why?
| | Epithelium | 1 | 2011 | 295 | 0.020 |
Why?
| | Cartilage | 1 | 2011 | 182 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2010 | 262 | 0.020 |
Why?
| | Survival Analysis | 1 | 2012 | 1211 | 0.020 |
Why?
| | Zebrafish | 1 | 2013 | 412 | 0.020 |
Why?
| | Chondrocytes | 1 | 2011 | 199 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2010 | 402 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 1998 | 1481 | 0.020 |
Why?
| | Molecular Dynamics Simulation | 1 | 2010 | 201 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 1796 | 0.020 |
Why?
| | Drug Combinations | 1 | 2009 | 287 | 0.020 |
Why?
| | Autoantigens | 1 | 2011 | 396 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 993 | 0.020 |
Why?
| | Receptors, Interleukin-8B | 1 | 2007 | 23 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2010 | 1016 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2010 | 796 | 0.020 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2008 | 43 | 0.020 |
Why?
| | Biomedical Research | 1 | 2013 | 585 | 0.020 |
Why?
| | Alleles | 1 | 2010 | 789 | 0.020 |
Why?
| | Permeability | 1 | 2008 | 149 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 86 | 0.020 |
Why?
| | Tight Junctions | 1 | 2008 | 68 | 0.020 |
Why?
| | Mannose-Binding Lectin | 1 | 2007 | 20 | 0.020 |
Why?
| | Microcirculation | 1 | 2007 | 135 | 0.020 |
Why?
| | Vaccination | 1 | 2015 | 1204 | 0.020 |
Why?
| | Cattle | 1 | 2009 | 920 | 0.020 |
Why?
| | Syndrome | 1 | 2007 | 333 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 740 | 0.020 |
Why?
| | Rodentia | 1 | 2006 | 44 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 4410 | 0.020 |
Why?
| | Placenta Diseases | 1 | 2006 | 13 | 0.020 |
Why?
| | Base Sequence | 1 | 2010 | 2114 | 0.020 |
Why?
| | Antibodies, Antinuclear | 1 | 2006 | 58 | 0.020 |
Why?
| | Methacholine Chloride | 1 | 2006 | 47 | 0.020 |
Why?
| | Protein Transport | 1 | 2008 | 395 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2006 | 66 | 0.020 |
Why?
| | Head Injuries, Closed | 1 | 2006 | 49 | 0.020 |
Why?
| | fas Receptor | 1 | 2006 | 91 | 0.020 |
Why?
| | Synovial Membrane | 1 | 2006 | 75 | 0.020 |
Why?
| | Trachea | 1 | 2007 | 224 | 0.020 |
Why?
| | Embryo, Mammalian | 1 | 2006 | 213 | 0.020 |
Why?
| | Trauma Severity Indices | 1 | 2006 | 114 | 0.020 |
Why?
| | Models, Molecular | 1 | 2010 | 1369 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2012 | 2765 | 0.020 |
Why?
| | Cell Death | 1 | 2006 | 323 | 0.010 |
Why?
| | Interleukin-10 | 1 | 2006 | 299 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 2796 | 0.010 |
Why?
| | Swine | 1 | 2006 | 700 | 0.010 |
Why?
| | Peptides | 1 | 2009 | 848 | 0.010 |
Why?
| | Monocytes | 1 | 2006 | 504 | 0.010 |
Why?
| | Psychomotor Performance | 1 | 2006 | 280 | 0.010 |
Why?
| | Receptors, Vasopressin | 1 | 2003 | 18 | 0.010 |
Why?
| | Aquaporin 2 | 1 | 2003 | 1 | 0.010 |
Why?
| | Aquaporin 3 | 1 | 2003 | 1 | 0.010 |
Why?
| | Aquaporin 6 | 1 | 2003 | 1 | 0.010 |
Why?
| | Aquaporin 1 | 1 | 2003 | 3 | 0.010 |
Why?
| | Kidney Medulla | 1 | 2003 | 29 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2006 | 676 | 0.010 |
Why?
| | Behavior, Animal | 1 | 2006 | 458 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 2003 | 173 | 0.010 |
Why?
| | Cell Survival | 1 | 2006 | 1021 | 0.010 |
Why?
| | Models, Biological | 1 | 2010 | 1621 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2320 | 0.010 |
Why?
| | Aquaporin 4 | 1 | 2003 | 87 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 1842 | 0.010 |
Why?
| | Myocardial Infarction | 1 | 2009 | 927 | 0.010 |
Why?
| | Neoplasms | 1 | 2015 | 2097 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2003 | 430 | 0.010 |
Why?
| | Placenta | 1 | 2006 | 626 | 0.010 |
Why?
| | Asthma | 1 | 2011 | 2029 | 0.010 |
Why?
| | Brazil | 1 | 1998 | 89 | 0.010 |
Why?
| | Transients and Migrants | 1 | 1998 | 22 | 0.010 |
Why?
| | Age Distribution | 1 | 1998 | 342 | 0.010 |
Why?
|
|
Thurman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|